Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
accepted:
24
09
2022
pubmed:
6
11
2022
medline:
15
11
2022
entrez:
5
11
2022
Statut:
ppublish
Résumé
The impact of psoriasis, response to treatment, and patients' perceptions of treatment satisfaction vary by body area. We aimed to evaluate the level of response in lower limbs versus other body regions in patient with moderate to severe psoriasis treated with secukinumab and ustekinumab. Data were pooled from CLEAR and CLARITY trials, which included patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] score of ≥ 12) aged ≥ 18 years and a diagnosis of ≥ 6 months before randomisation. Patients received either secukinumab 300 mg or ustekinumab 45/90 mg. The PASI 100 responders and mean PASI scores at weeks 4, 12, 16, 28, 40 and 52 in the head and neck, trunk, upper limbs and lower limbs were measured. At baseline, analysis of PASI scores for each body region revealed that the lower limbs were the most severely affected body region in both treatment arms (mean PASI scores: secukinumab 24.0; ustekinumab 24.4). For both drugs, the highest clearance rates at week 52 were achieved in the trunk (secukinumab 85.2% vs ustekinumab 68.7%) and head and neck (80.7% vs 68.9%), followed by the upper limbs (72.6% vs 61.9%) and lower limbs (68.1% vs 57.2%). At week 52, the mean PASI score was higher in the lower limbs in both treatment arms versus other body regions. Lower limbs were the most severely affected and most difficult-to-treat regions in patients with psoriasis. Consistent with the individual results of both studies, secukinumab demonstrated numerically faster and higher skin clearance than ustekinumab in all body regions. CLEAR: NCT02074982; CLARITY: NCT02826603.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of psoriasis, response to treatment, and patients' perceptions of treatment satisfaction vary by body area.
OBJECTIVES
OBJECTIVE
We aimed to evaluate the level of response in lower limbs versus other body regions in patient with moderate to severe psoriasis treated with secukinumab and ustekinumab.
METHODS
METHODS
Data were pooled from CLEAR and CLARITY trials, which included patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] score of ≥ 12) aged ≥ 18 years and a diagnosis of ≥ 6 months before randomisation. Patients received either secukinumab 300 mg or ustekinumab 45/90 mg. The PASI 100 responders and mean PASI scores at weeks 4, 12, 16, 28, 40 and 52 in the head and neck, trunk, upper limbs and lower limbs were measured.
RESULTS
RESULTS
At baseline, analysis of PASI scores for each body region revealed that the lower limbs were the most severely affected body region in both treatment arms (mean PASI scores: secukinumab 24.0; ustekinumab 24.4). For both drugs, the highest clearance rates at week 52 were achieved in the trunk (secukinumab 85.2% vs ustekinumab 68.7%) and head and neck (80.7% vs 68.9%), followed by the upper limbs (72.6% vs 61.9%) and lower limbs (68.1% vs 57.2%). At week 52, the mean PASI score was higher in the lower limbs in both treatment arms versus other body regions.
CONCLUSIONS
CONCLUSIONS
Lower limbs were the most severely affected and most difficult-to-treat regions in patients with psoriasis. Consistent with the individual results of both studies, secukinumab demonstrated numerically faster and higher skin clearance than ustekinumab in all body regions.
CLINICAL TRIAL REGISTRATION
BACKGROUND
CLEAR: NCT02074982; CLARITY: NCT02826603.
Identifiants
pubmed: 36334236
doi: 10.1007/s40259-022-00558-2
pii: 10.1007/s40259-022-00558-2
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
secukinumab
DLG4EML025
Dermatologic Agents
0
Antibodies, Monoclonal
0
Banques de données
ClinicalTrials.gov
['NCT02074982', 'NCT02826603']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
781-789Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–71.
doi: 10.1016/S0140-6736(07)61128-3
pubmed: 17658397
Blauvelt A, Muram TM, See K, Mallinckrodt CH, Crowley JJ, van de Kerkhof P. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatol Treat. 2018;29:220–9.
doi: 10.1080/09546634.2017.1365114
Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J. Efficacy of secukinumab on moderate to severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6:639–47.
doi: 10.1007/s13555-016-0140-7
pubmed: 27576559
pmcid: 5120629
Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb). 2018;8:571–9.
doi: 10.1007/s13555-018-0265-y
pubmed: 30334147
pmcid: 6261116
Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen Y-K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–17.
doi: 10.1016/j.jaad.2016.11.041
pubmed: 28057360
Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484–93.
doi: 10.1111/bjd.13348
pubmed: 25132411
Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60-9.e9.
doi: 10.1016/j.jaad.2016.08.008
pubmed: 27663079
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate to severe plaque psoriasis. N Engl J Med. 2016;375:345–56.
doi: 10.1056/NEJMoa1512711
pubmed: 27299809
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371:326–38.
doi: 10.1056/NEJMoa1314258
pubmed: 25007392
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–28.
doi: 10.1056/NEJMoa1503824
pubmed: 26422722
Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, et al. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: subgroup analysis from the CLEAR study. J Dermatol. 2019;46:752–8.
doi: 10.1111/1346-8138.15004
pubmed: 31342560
Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–9.
doi: 10.1016/j.jaad.2015.05.013
pubmed: 26092291
Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014;70:146–67.
doi: 10.1016/j.jaad.2013.08.042
pubmed: 24126079
European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf . Accessed 10 Jun 2021.
Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75:77-82.e7.
doi: 10.1016/j.jaad.2016.03.026
pubmed: 27206759
Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(871–81):e1-30.
Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978;157:238–44.
doi: 10.1159/000250839
pubmed: 357213
Armstrong AW, Vender R, Kircik L. Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis. J Clin Aesthet Dermatol. 2016;9:S12–6.
pubmed: 28439342
pmcid: 5395240
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–48.
doi: 10.1056/NEJMoa1505066
pubmed: 26699169
Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21:111.
doi: 10.1186/s13075-019-1882-2
pubmed: 31046809
pmcid: 6498580
Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161–73.
doi: 10.1111/jdv.16124
pubmed: 31785165
Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73:110–20.
doi: 10.1002/art.41477
pubmed: 32770640
Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–72.
doi: 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E
pubmed: 9595616
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27–40.
doi: 10.1016/j.jaad.2018.06.057
pubmed: 30017705
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient. Focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.
doi: 10.1016/j.jaad.2018.06.056
pubmed: 30017706
Griffiths CE, Sterry W, Brock F, Dilleen M, Stefanidis D, Germain JM, et al. Pattern of response in patients with moderate to severe psoriasis treated with etanercept. Br J Dermatol. 2015;172:230–8.
doi: 10.1111/bjd.13139
pubmed: 24861696
Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira HD. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate to severe psoriasis. J Drugs Dermatol. 2014;13:554–62.
pubmed: 24809878
Sojević Timotijević Z, Majcan P, Trajković G, Relić M, Novaković T, Mirković M, et al. The impact of changes in Psoriasis Area and Severity Index by body region on quality of life in patients with psoriasis. Acta Dermatovenerol Croat. 2017;25:215–22.
pubmed: 29252174